Eli Lilly and Company (LLY) Set to Announce Quarterly Earnings on Thursday

Key Points

• Eli Lilly is scheduled to report Q3 2026 earnings before the market opens on October 29. Analysts expect $5.63 in adjusted earnings per share and $22.56 billion in revenue, compared with full-year guidance of $35.50–$36.50 EPS.
• The company’s prior quarter showed strong momentum, with EPS of $8.38 beating estimates and revenue rising 47.7% year over year to $22.97 billion. Investors will watch whether demand for Mounjaro and Zepbound offsets declining realized prices.
• Analysts remain broadly bullish, but valuation and competition are risks. Lilly has a “Moderate Buy” consensus rating and an average price target of $1,317.93, while Novo Nordisk’s obesity-drug progress and Lilly’s premium valuation could pressure the stock.

Eli Lilly and Company (NYSE:LLY - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Eli Lilly and Company to announce earnings of $5.63 per share and revenue of $22.56 billion for the quarter. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Parties can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 10:00 AM ET.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the company posted $6.31 earnings per share. The business's revenue for the quarter was up 47.7% on a year-over-year basis. On average, analysts expect Eli Lilly and Company to post $33.56 EPS for the current fiscal year and $47.18 EPS for the next fiscal year.

Eli Lilly and Company Stock Down 0.9%

LLY stock opened at $1,271.89 on Thursday. The company's 50 day moving average price is $1,182.84 and its 200 day moving average price is $1,116.53. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $793.82 and a fifty-two week high of $1,311.75. The firm has a market capitalization of $1.20 trillion, a price-to-earnings ratio of 40.76, a PEG ratio of 1.71 and a beta of 0.46.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LLY. Leerink Partners lifted their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a research note on Wednesday. BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. Weiss Ratings raised shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 15th. HSBC raised their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a report on Thursday, September 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a report on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,317.93.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst target and expected earnings strength: Goldman Sachs raised its price target to $1,413 from $1,371 while maintaining a Buy rating. The firm reportedly expects Eli Lilly to beat third-quarter estimates and raise its outlook, supported by international Mounjaro growth and Zepbound volume gains. Goldman Sachs raises Eli Lilly price target
• Positive Sentiment: International manufacturing expansion: Eli Lilly signed Abu Dhabi agreements involving local packaging and advanced pharmaceutical contract manufacturing for weight-loss medicines. The company also entered a drug-delivery partnership with China’s Metis TechBio valued at up to $1.1 billion, potentially strengthening supply capacity and product-delivery capabilities. Eli Lilly Abu Dhabi packaging deal
• Positive Sentiment: Pipeline expansion: One-year Phase 3 SHINE-2 data showed Omvoh sustained clinical-remission benefits in children with ulcerative colitis, including patients who had previously failed biologic treatments. Regulatory approval could expand Lilly’s inflammatory bowel disease franchise. Pediatric ulcerative colitis data
• Neutral Sentiment: Strong growth, but pricing is a key upcoming issue: Second-quarter revenue increased 48% to approximately $23 billion as medicine volume rose 60%, while realized price per unit declined 13%. Investors will focus on whether continued demand and volume growth can offset pricing pressure when third-quarter results are released on October 29. Eli Lilly volume and pricing analysis
• Negative Sentiment: Competition and valuation risks: Novo Nordisk’s CagriSema produced 25% weight loss in women, reinforcing competitive pressure in the obesity-treatment market. After a substantial rally and record valuation, investors may also be taking profits or demanding stronger evidence that Lilly’s growth can justify its premium multiple. Novo Nordisk CagriSema results

Insider Activity

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.